May 14, Tasly TRANSGENE contract with the French decided to jointly set up Tasly Creation Kit (Tianjin) Biotechnology Pharmaceutical Co., Ltd.. This can be seen as domestic pharmaceutical companies with foreign pharmaceutical companies, "marriage" in another case.
In fact, in recent years, similar to the "Chinese and foreign joint" phenomenon is becoming frequent, such as the acquisition of Merck Group in Suzhou Thai beads, Chinese vaccine company Novartis acquired 85% stake in Zhejiang Tianyuan, CRL acquisition of U.S. drug research company Wuxi Pharmatech WuXi so. The industry view, it also revealed a certain extent the international pharmaceutical giant in China's promising biomedical market. Research and development cooperation need to grasp the initiative
Tasly in the acceptance of the China Securities newspaper interview that the company's partners the French TRANSGENE is a research enterprise, the company in cooperation with hope the introduction of new products and technologies, but only at the bilateral cooperation the initial stage, both sides decided to establish a joint venture only, some factions to form a small team of professional presence, has yet to find a specific product in-depth cooperation.
Recently, the largest pharmaceutical chemistry services company in Wuxi, WuXi PharmaTech is the United States pharmaceutical research company CharlesRiver Laboratories (CRL) about 16 billion dollars to acquire.
Analysts said the domestic pharmaceutical companies to seek foreign strategic partners is becoming a trend, but the specific effects and can not guarantee the cooperation, because, after all, drug research and development in the biological stronger foreign enterprises, in cooperation Chinese enterprises may only play a "manufacturing plant" role. Security researchers in the East China Sea Qu
"i seem to get rid of in the field of biological medicine in the status of low-end chain, only to grasp the initiative in research and development, from this point of view, if the cooperative R & D center in China to foreign enterprises in China transfer, such cooperation to be more ideal number.
Tasly cooperation with the French side of the aim of integrated strengths of the two R & D centers in China, and gradually establish a research platform for biological drugs, and effective use of the French side to improve the company's technology R & D innovation. Analysts believe that, although cooperation has just begun, but the domestic enterprises to participate in R & D process is very important, can not be satisfied simply to introduce products or technologies.
Optimistic about the international pharmaceutical giant domestic market
Listed companies in China seems to seek strategic partners has become a world-renowned pharmaceutical companies to enlarge and strengthen a trend. In the industry experts, the move also shows that foreign pharmaceutical companies largely on the Chinese market remains positive, especially for China policy support powerhouse?? Biomedical industry prospects. Pfizer, Merck executives and other international pharmaceutical giant has publicly said it is actively seeking partners in China.
Recent years, the pharmaceutical industry to maintain growth in profitability, including biopharmaceutical truly become a "leader." The first two months of this year, China's pharmaceutical industry had accumulated a total profit of 11.165 billion yuan, up 23.18 percent year on year growth, which increase the profitability of biopharmaceutical 43.4%.
In fact, in the international market, pharmaceutical companies and biotechnology industry is also quietly integrate each other's needs. Many pharmaceutical giant in the face of a large number of pharmaceutical patent expires, the new patent R & D increasingly difficult to increase the challenge, their ability to inhibit the development of the development costs of new drugs has increased significantly, while new biotech R & D is relatively more active However, the strength of these enterprises are small scale, strong financial strength of desire for support.
Complementary characteristics of both the international pharmaceutical giant, is interested in biotechnology companies, also makes the basis of bilateral cooperation have. Now it seems that the international pharmaceutical giant is also trying to countries such as China and India to find a suitable bio-pharmaceutical enterprises, outsourcing or R & D outsourcing of production to enter the market, which is the direct acquisition of the current set up joint ventures and other forms The "foreign marriage" the reason why frequent. I am a professional writer from China Chemicals Products, which contains a great deal of information about car paint sealants , auto fuel saver, welcome to visit!
Related Articles -
car paint sealants, auto fuel saver,
|
